OKYO Pharma Ltd
urcosimod
neuropathic corneal pain (NCP)
Resolved
7days ago
Catalyst readout · ~ Jun 30, 2026 estimated
What's at stake
A key catalyst for urcosimod (neuropathic corneal pain (NCP)) is expected ~ Jun 30, 2026.
Primary source
· SEC 6-K
verified 14h ago
“OKYO planning to initiate a 150-patient multiple-dose Phase 2b/3 study in the first half of 2026.”